Innoviva Inc

INVA is locked in a Stage 4 decline with confirmed lower highs/lower lows and a bearish support failure pattern. Though oversold, Mean Reversion Eligible is No, so no countertrend buying flag. The medium-term bias remains bearish, favoring sells only on rallies into the declining 9/21 EMA zone. Short-term timing is unfavorable due to oversold extension, so execution should be deferred (Trim) rather than immediate selling.

• ↑Dr. Reddy’s partnership extends XACDURO royalties across international markets.
• ↑BTIG maintains Buy/$42 target; median $39 price target implies +65% upside.
• ↓Q1 EPS of –$0.05 missed $0.40 estimate, highlighting execution issues.